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Heart attack is a common and deadly condition which is the major cause of death in most 
developed countries. Myocardial infarction, commonly known as heart attack, occurs when there 
is a disruption in blood supply to parts of the heart due to occlusion of a coronary artery leading 
to excessive cell death. Over the past few decades, heart transplantation has been the backbone 
of therapy for the treatment of heart failure and it has proved to be one of the most effective 
therapies for end-stage heart failure. But the major obstacles with heart transplantation are the 
limited supply of suitable donors and lifelong immune suppression which often causes serious 
consequences.  
Several other therapies are experimented for the treatment of the infarcted myocardium, of which 
the tissue engineering approach is gaining much attention. Cardiac tissue engineering promises 
to bring about a change in the treatment of patients with myocardial infarction and aims at 
providing cutting-edge solutions to end-stage heart failure. To date, there are no successful 
models of bioengineered cardiac implant that can suitably mimic the anatomy, physiology and 
biological stability of a healthy heart wall.  
To address this challenge, here we report the development and analysis of electrospun 
nanofibrous composite scaffolds using natural proteins that mimic the native myocardial 
environment. It is necessary to understand the pathological processes following infarction of 
which massive cell loss is very critical as the myocardial tissue lacks significant intrinsic 
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regenerative capability to replace lost cells. Therefore, it is essential to provide a physiologically 
relevant milieu for the cells to proliferate. The novelty in our idea is the use of natural body 
proteins – fibrinogen, collagen and gelatin for the fabrication of a fully natural composite 
scaffold, supplemented with human cardiac cells which can act as a temporary extracellular 
matrix until repair. Fibrinogen is a globular blood plasma protein and plays significant roles in 
hemostasis, wound healing, inflammation, angiogenesis, neoplasia, etc. In the case of the 
myocardium, fibrinogen along with fibronectin is crucial for the formation of “primary matrix” 
(in developing the granulation tissue) which functions as a meshwork for the deposition and 
adhesion of other matrix proteins such as interstitial collagens post myocardial infarction. The 
use of this blood plasma protein along with another natural body protein such as collagen or 
gelatin will be ideal to act as a temporary extracellular matrix to support the regeneration of the 
infarcted myocardium.  
We have proven that the fabrication of a fully natural nanofibrous composite scaffold using 
electrospinning process is biocompatible, closely imitates the myocardial extracellular-matrix 
and offers the possibility to enhance cell proliferation. The optimal amount of fibrinogen in the 
natural composite for cardiac tissue engineering application is identified. To improve the 
mechanical integrity of the natural polymeric scaffolds they were cross-linked and the tensile 
properties of the cross-linked electrospun natural polymeric scaffolds were studied and found to 
be close to the mechanical properties of the heart.  
Our electrospun natural polymeric scaffolds were found to provide better biocompatibility, 
hydrophilicity, biodegradability as well as suitable mechanical properties as desired for cardiac 
tissue engineering. The cell-scaffold interactions of human cardiomyocytes with the electrospun 
natural polymeric scaffolds were analyzed in detail by cell proliferation, confocal microscopic 
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analysis for the expression of four cardiac-specific marker proteins like Actinin, Troponin-T, 
Connexin-43, Myosin heavy chain. 
We established the cardiomyogenic differential potential of human adipose-derived stem cells 
which is found to be largely enhanced by the fabricated electrospun natural polymeric composite 
substrates. Characterization and dual immunofluorescent analysis showed that our fabricated 
nanofibrous scaffolds greatly promoted differentiation of adipose-derived stem cells, integration 
with the co-cultured cardiomyocytes, cell attachment and growth because of their biological 
components.  
To our knowledge, the idea of using electrospun fully natural-protein composite nanofibrous 
scaffolds supplemented with human adipose-derived stem cells/cardiomyocytes for the purpose 
of cardiac tissue engineering is a novel idea and they have the immense potential to be used for 










The heart is the muscular organ of the circulatory system that constantly pumps blood throughout 
the body. The heart is made up of the cardiac muscle tissue which is very strong and has the 
ability to contract and relax rhythmically throughout the life span of a human. The fundamental 
concept of circulation was developed by Harvey who suggested that the circulation of the blood 
is caused by pumping of the heart. The human heart has four chambers. The upper two chambers 
are the left and right atrium which receives blood coming to the heart and delivers it to the lower 
two chambers – left and right ventricles which pumps blood away from the heart by rhythmic 
contractions. The human heart can be considered as two pumps – the right side pumps de-
oxygenated blood from the systemic veins into the pulmonary circulation to the lungs, and the 
left side of the heart receives the oxygenated blood from the lungs and pumps it into the systemic 
circulation through the aorta for circulation to the rest of the body. Systole and diastole are the 
contraction and relaxation of the cardiac muscle and there is increased pressure due to 
contraction in the ventricles (systolic pressure) and decrease in pressure due to the relaxation of 
the ventricles (diastolic pressure). The pumping motion of the heart is obtained due to the 
contraction and relaxation of the heart muscle which coordinated by a meshwork of nerve fibers. 
The heart is surrounded by a connective tissue layer which is the pericardium and there are three 
layers in the outer wall of the heart – epicardium or visceral pericardium, myocardium and 
endocardium. Epicardium is the outer layer and the innermost layer is the endocardium which is 
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in contact with the blood that the heart pumps and consists of blood vessels and heart valves. The 
myocardium is the thickest contractile middle layer of the heart wall and it is the ventricular wall 
between the epicardium and endocardium [1]. It is composed of cardiac muscle cells that form 
the bulk of the heart and consists of muscle fibers and blood vessels which are connected and 
interspersed by a network of connective tissue. The uniqueness of heart lies in its dynamic 
functionality which requires sophisticated tissue architecture with specialized cellular and 
extracellular components. Every excitation and contraction cycle of the cardiac muscle involves 
a number of mechanical events and recent studies have shown more significant association of the 
ECM in all aspects of the electromechanically active myocardium than it was previously 
believed. Proteins present in the myocardial extracellular matrix (ECM) include collagen 
subtypes, glycoproteins, elastin, etc. and these proteins play a vital role in the organization and 
support of myocytes and the capillary network. Proteoglycans and other glycoproteins aid in the 
hydration of the ECM and act as lubricants for the cardiac contractile machinery. Fibronectin is a 
glycoprotein which is localized homogeneously throughout the extracellular space in which 
cardiac myocytes and collagens are embedded.  
1.2 Myocardial Infarction 
Heart disease is the leading cause of death and disability in both industrialized nations and the 
developing world, accounting for approximately 40% of all human mortality, more than all 
cancers combined, and it is becoming a leading global threat of the 21
st
 century. Heart attack or 
myocardial infarction (MI) is a condition in which there is a blockage or deterioration in the 
pumping efficiency of the heart resulting in fluid congestion or inadequate blood flow to tissues. 
This is a progressive disorder in which damage to the heart causes weakening of the 
cardiovascular system and is induced by several underlying diseases, which includes ischemic 
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heart disease with or without an episode of acute myocardial infarction, hypertensive heart 
disease, valvular heart disease and primary myocardial disease. MI occurs when one or more of 
the blood vessels supplying the heart occlude and there is decrease in the supply of nutrients and 
oxygen to that portion of the heart. If the blood flow is not restored immediately, it will cause 
irreversible cell death and the adult heart cannot repair as the mature cardiomyocytes are unable 
to divide. MI leads to permanent loss of cardiac tissue, ultimately leading to end-stage heart 
failure and the pathological changes after MI are characterized by an initial inflammatory 
response and loss of cardiomyocytes. The death of cardiomyocytes initiates migration of 
macrophages, monocytes, and neutrophils into the infarct area, initiating the inflammatory 
response. Furthermore, matrix malleoproteases set off leading to infarct expansion and 
degradation of the ECM resulting in myocyte slippage. As a consequence of this, there is 
weakening in the collagen scaffold which eventually causes wall thinning and ventricular 
dilation. During the second phase, there is resistance to rupture and deformation due to the 
increase in the deposition of fibrillar, cross-linked collagen. Heart failure is generally 
accompanied by remodeling, a process which involves change in the ventricular shape and 
dimension. Remodeling occurs with an increase in myocardial and interstitial mass and negative 
left ventricular (LV) remodeling, and cause increased wall stress on the remaining viable 
myocardium. Various factors/processes such as myocyte hypertrophy, myocyte slippage and 
interstitial growth induce the remodeling process resulting in LV dilation. It is suggested that LV 
remodeling may contribute independently to the progression of heart failure. The consequence of 
MI is the formation of scar tissue which does not have contractile, mechanical and electrical 
properties as the native myocardium. The scar tissue decreases the pumping efficiency of the 
ventricles and certain compensatory mechanisms activate in response to the reduced cardiac 
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output which places an extra burden on the already weakened heart accelerating end-stage heart 
failure [2]. Heart failure or MI remains one of the biggest challenges in the field of medical 
sciences with great improvements are expected to progress in the tissue engineering (TE) field 











1.3 Hypothesis and objectives 
Hypothesis 
This project is to develop an ideal substrate for myocardial tissue engineering using electrospun 
natural proteins. We hypothesize that the use of cardiac-specific proteins, which are of 
significance post MI such as fibrinogen, along with another natural protein (collagen) will 
provide a physiologically relevant environment for the cardiac myocytes to adhere and 
proliferate and also promote the possibility of mimicking the myocardial ECM in terms of 
biocompatibility, morphology, surface characteristics, tensile strength and stiffness, which are 
critical for the regeneration of the infarcted myocardium.  
Objectives 
 Develop a temporary cardiac-specific extracellular matrix to help in myocardial repair by 
fabricating a fully natural polymeric nanofibrous composite scaffold by electrospinning. 
 Optimize the composition of the natural proteins in the composite matrix and the 
processing parameters for electrospinning. 
 Improve the mechanical properties of the natural polymeric composite in order to suit for 
cardiac tissue engineering application. 
 Evaluate the morphological, chemical and mechanical properties of the fabricated natural 
polymeric scaffolds. 
 Determine the adhesion and proliferation of human cardiomyocytes and investigate the 
differentiation of ADSCs on the fabricated natural polymeric scaffolds by protein 






Despite extensive surgical treatments, the number of patients with heart failure continues to 
increase. Over the past 30 years, heart transplantation has been the backbone of therapy for the 
treatment of heart failure and it has proved to be one of the most effective therapies for end-stage 
heart failure. Unfortunately, the major obstacle with heart transplantation is the limited supply of 
suitable donors. In addition, lifelong immune suppression often causes serious consequences [3]. 
Another surgical approach for the treatment of MI which is gaining significant attention in the 
past decade is the TE approach which aims in mimicking the myocardial ECM. The ECM, by 
definition, is the organic matter that is found between the cells in plants and animals. The ECM 
is a relatively stable structural material that lies under the epithelia and surrounds the connective 
tissue cells and provides a stable framework for multicellular organisms under gravity and 
physical loading, whereby it maintains the integrity of tissues enabling physiological 
functioning. Over the years, there is a gradual change in our understanding of the ECM as a 
static ‘connective tissue’ that binds everything together to one of the dynamic biomaterial that 
performs multiple functions such as providing strength and elasticity, activating growth factors 
during development and controlling their availability, cell-surface receptor interactions etc. 
Besides, ECM is essential for morphogenesis and assist in the regeneration of multicellular 
organisms and tissues. The integrin receptors on the cell surface along with the ECM can be 
pictured as intricate nanodevices that allow cells to physically organize their 3D environment, 
and sense and respond to various types of mechanical stress [4]. Although the composition of 
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ECM represents a complex alloy of variable members of diverse protein families such as the 
collagens, proteoglycans, glycosaminoglycans and elastin, their main function is to support the 
tissue with specific mechanical and biochemical properties. For example, the collagens are a 
source of strength to the tissues; elastin and proteoglycans provide matrix resiliency and other 
structural glycoproteins aid in inducing tissue cohesiveness.  
2.2 Tissue Engineering 
TE is a significantly advancing multi-disciplinary field that engages the principles of 
engineering, biology and life sciences with the ultimate goal of restoring the native tissue 
function [5]. It enables the injured tissue to regenerate using a biomimetic approach with the help 
of three important factors such as biomaterial-based supporting scaffolds, functional cells and 
specific growth factors, among which the biomaterials play a dominant role as they can control 
and improve the cell retention, proliferation and differentiation. The objective of TE is to repair 
the injured tissues by supplementing functional cells, supporting scaffolds, growth-factors or 
genes and electric or physiologic signals to the organs when essential. Cardiac tissue engineering 
(CTE) has grown as an indispensable field of research considering the increase in the number of 
heart failures and it has shown tremendous improvement in the past 10 years. Although it is very 
difficult to produce a perfect replica of the native cardiac tissue, there are certain important 
factors to be satisfied for the development of such myocardial models [6]: (i) clinical viable cell 
source with physiological composition of different cell types for each tissue component; (ii) 
biomaterial properties that closely match the physiological composition of cardiac ECM; (iii) 
easily controllable biomaterial degradation kinetics with degradation products being safely 
removed from the body; (iv) tissue construct needs to be non-thrombogenic and immune 
tolerant; (v) functional, biological, and histological properties of the tissue constructs should be 
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comparable to normal mammalian cardiovascular tissue; and (vi) the tissue construct need to 
withstand physiological stresses within the complex fluid environment of the cardiovascular 
system. Current, TE modalities include (i) in vitro engineered cardiac tissue approach – culturing 
cells on a biomaterial scaffold in vitro and implanting the tissue into the epicardial surface (ii) 
Implementation of a cardiac patch – populating the designed patch with isolated cells in vitro and 
further implanted in vivo (iii) Injectable systems – injecting cells and/or scaffold directly into the 
infarcted wall to create in situ engineered cardiac tissue. A cardiac patch is a three-dimensional 
matrix comprised of natural or synthetic biomaterials that host the cells and provide mechanical 
and structural support for the injured heart. By culturing contractile cells onto a 3D scaffold, the 
formation of functional cardiac patches can be induced. Implantation of these patch materials 
involves an invasive open chest procedure, such as sternotomy or thoracotomy. Patch materials 
can also be sutured to the epicardial surface of the heart, limiting the region of therapeutic 
benefits. These tissue-engineered patches may be utilized in cases of acute MI, augmenting lost 
contractile function of the left ventricle.  
2.3 Biomaterials  
A biomaterial is defined as a non-viable material used in a medical device, intended to interact 
with biological systems [7, 8]. Biomaterials were mostly studied for applications in orthopedics 
and for development of prosthetics. Recently, novel molecularly designed biomaterials which 
can deliver growth factors and control the environment of transplanted cells are being developed. 
Biomaterials are required for most of the TE approaches and the major functions of an ideal 
biomaterial are to enhance cell adhesion, proliferation and differentiation. The general 
requirements for a biomaterial are that it should be biocompatible - not induce an inflammatory 
response, biomimetic – reflect the ECM of the tissue, biodegradable – possess appropriate 
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degradation kinetics and degradation products should be non-toxic, and possess suitable 
mechanical integrity. It is also essential that the biomaterial aids in vivo revascularization as well 
as integration with the host tissue. There are additional specific requirements for a biomaterial to 
be applied for CTE. It includes that the biomaterial is able to tolerate the continuous 
stretching/relaxing motion of the myocardium that occurs at each heartbeat. It is favorable if the 
biomaterial exhibits a nonlinear elasticity of heart muscle such that it could reshape with the 
heart and thus provide mechanical support throughout the beating mechanism. Other specific 
criteria for CTE are that the biomaterial should encourage cardiomyocyte alignment and 
maturation in vitro before implantation or in vivo and also, the biomaterial should enable 
electrical integration of engineered graft with the native tissue to allow synchronized beating 
between the artificial construct and the heart. Many natural and synthetic polymeric biomaterials 
such as collagen, gelatin, alginate, fibrinogen, etc. and PGA, PLLA, PCL, PGS, PNIPAAM, etc. 
respectively, are used for CTE and these biomaterials are used in several forms such as 
nanofibers, microspheres, injectables, meshes, sponges, etc. Biomaterials used in the form of 
injectable without inclusion of cells can decrease remodeling after MI by increasing thickness of 
the infarct leading to decreased wall stress on surviving myocardium [9, 10]. Fetal rat myocardial 
cells seeded into alginate sponges produced by freeze-drying technique were developed to 
engineered heart construct and were implanted into rat hearts with myocardial infarct. Intensive 
neovascularization was found and the specimens showed almost complete disappearance of the 
scaffold and good integration into the host after 9 weeks [11]. It is, therefore, preferred to choose 
the biomaterial or tailor-design the properties in order to produce robust yet flexible, 
contractible, electrophysiologically stable, readily vascularized myocardial construct. Table 1 












2.4 Natural Proteins 
The selection of biomaterials for scaffold design is a major criterion and should be carefully 
considered based on the biodegradability of the polymer, its ability to deliver and foster cells and 
their mechanical properties for appropriate applications.   Natural, ECM-derived proteins are 
apparently the first choice for soft TE, since they provide a physiologically relevant and 
recognizable platform for the cells to attach, proliferate and differentiate. Moreover, they are 
biocompatible, non-toxic, possess appropriate degradation kinetics and generate mild 
inflammatory response. On the other hand, synthetic polymers are non-physiological and act 
mainly to provide a physical or mechanical support to hold the cells. A slight change in the 
environmental pH upon degradation of the synthetic polymers is also harmful to the surrounding 
cells and in addition, the polarity, water absorption and degradation properties raise questions 
against the medical suitability of these synthetic polymeric scaffolds [13].  
 
2.4.1 Collagen 
The most plentiful proteins in the ECM are the collagen family of proteins and collagens form 
the fundamental organic matrix of the bone, skin, arteries, ligaments, cartilage and most of the 
ECM in general. Contributing ~30% of the total protein mass in mammals, the collagenous 
proteins are a broad class of molecules found with extreme heterogeneity. To date, 29 types of 
collagen have been identified in the collagen superfamily and these 29 types of collagen are 
discriminated by considerable complexity and diversity in their structure, their splice variants 
and the presence of additional non-helical domains, their assembly and their function [14]. 
Collagen network contribute chiefly to the cardiac ECM and they play a vital role in the 
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myocardial structure and function. Collagen provides strength and stiffness to the myocardium 
and establishes a structural framework for the myocytes and provides myocyte-to-myocyte 
connections (collagen struts) that are vital in adhering the cells. Five collagen isoforms are 
present in the myocardium – types I, III, IV, V and VI with the most abundant forms of collagen 
being type I and type III collagens each contributing 80% and 12% respectively and they also 
constitute for the bulk scar tissue following MI [15, 16]. Type I and type III collagen molecules 
form aggregate struts of varying thickness and are widely distributed between myocytes and 
among muscle fibers [17, 18] whereas type IV collagen arrange themselves to form end to end 
aggregates characterized by a fishnet appearance in the basement membrane of cardiac myocytes 
and fibroblasts [19, 20]. Type VI collagen is present as fine filaments in the myocardium 
oriented perpendicularly opposite to other collagen fibers [21]. Collagen types present in the 
myocardium are relatively insoluble and are characterized by abundant inter- and intra-molecular 
covalent cross-linkage [22]. Also, a hierarchy of decreasing tensile strength exists among cardiac 
collagen (type I > type III > type VI and fibronectin > basement membranes) so that changes 
induced by contraction and relaxation could be effectively distributed throughout the heart [16]. 
Przyklenk et al [23] found that the stiffness and tensile strength of the myocardium correlated 
directly with collagen content and as such, a collagen-rich matrix is critical in maintaining the 
integrity of the cardiac.  
 
2.4.2 Gelatin 
Gelatin is a natural glycoprotein and an irreversibly hydrolysed form of collagen and the protein 
pathogens are removed during denaturing hydrolysis. Gelatin is derived from collagen found 
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inside animals’ skin and bones. It is obtained mainly from the most abundant collagen (type I), 
present in bone and skin (main sources include pig skin, cattle bones, cattle hide etc). A 
negatively charged acidic gelatin or a positively charged basic gelatin can be produced by 
changing the isoelectric point. This exclusive property of tailoring the electrical nature nature of 
gelatin can be applied for the sustained release of proteins from polymer matrices [24]. Gelatin is 
commonly used in several forms such as nanofibers, hydrogels, microspheres, etc. for various TE 
[25 - 29] and drug delivery applications [30 - 32]. Gelatin is applied as a gelling agent the food 
industry (e.g. gelling and foaming agent), in the pharmaceutical industry (e.g. soft and hard 
capsules, microspheres), in the biomedical field for wound dressing and TE and also in 
photography and cosmetic manufacturing. Gelfoam, a commercially available gelatin mesh has 
been used as a biodegradable scaffold to support the 3-dimensional growth of seeded cells such 
as fetal rat ventricular cardiomyocytes, gastric smooth muscle cells, skin fibroblasts and adult 
human atrial cardiomyocytes [33]. Recently, a group in China used gelatin microspheres to 
deliver vascular endothelial growth factor (VEGF) to enhance the efficacy of bone marrow 
mesenchymal stem cell transplantation in swine model of MI [34]. Gelatin is considered more 
advantageous compared to collagen because of its (i) abundant availability at an affordable cost; 
(ii) lower antigenicity than collagen; (iii) biodegradability and biocompatibility in physiological 
environments; (iv) ability to tailor the electrical nature of gelatin and flexibility in processing to 
suit diverse applications; The arginine-glycine-aspartic (RGD) sequences of collagen is also 






Fibrinogen is a ubiquitous glycoprotein present in the human blood plasma at a concentration of 
about 2.0 - 4.5 g/L [36]. It is a (slightly) bent and twisted trinodular molecule consisting of six 
polypeptide chains 2Aα, 2Bβ and 2γ which are bound together by 29 disulfide bonds [37, 38]. 
Fibrinogen plays a major role not only in blood clotting and wound healing but also in fibroblast 
proliferation and defense mechanisms against infection. Of the total fibrinogen content in the 
human body, 80 – 90% is found in the blood plasma and it is vital for hemostasis, wound 
healing, inflammation, angiogenesis, neoplasia and performs myriad other functions like serving 
as an essential co-factor for platelet aggregation, a determinant of blood rheology, etc. The 
degraded products of fibrinogen and fibrin stimulate the migration and proliferation of smooth 
muscle cells and fibrinogen is also associated with cultured endothelial cells and helps in 
migration [39]. It is also believed that the specific and tightly controlled intermolecular 
interactions of fibrinogen domains influence several other aspects of cellular function and 
developmental biology. When fibrinogen is exposed to thrombin, two peptides are cleaved to 
produce fibrin monomers which in the presence of Ca
2+
 and factor XIII lead to the assembly of 
stable fibrous clots (insoluble gels) and/or other fibrous structures. These stable structures 
function as nature’s provisional matrix, on which tissues rebuild and repair themselves. This 
process is similar to the TE objective and taking this cue, fibrinogen along with another natural 






2.5 Nanofibers by electrospinning 
2.5.1 Electrospinning – Basic principle 
Electrospinning refers to the technique of drawing very fine fibers on a nano scale by applying 
high electric potential and this method is applicable for any fusible polymer. The technique 
involves pumping a polymer solution or melt through a thin nozzle. The nozzle is connected to a 
high voltage of the order of 30KV thereby serving as an electrode. A grounded collector is used 
to collect the electro spun polymer. On pumping the polymer melt out, through the nozzle, the 
high electric field causes the polymer droplet to separate due to high electrostatic forces of 
repulsion on its way to the collector. This electrified jet undergoes elongation and whipping, 
leading to the formation of a long thin thread. The solvent subsequently evaporates and the 
polymer solidifies producing fibers of nano to micro diameter [40]. Electrospinning process does 
not require high temperature and therefore, it is suited for the manufacture of fibers using large 
and complex molecules. The major parameters influencing this process include molecular weight 
of the polymer, solution properties, electric potential, flow rate, needle diameter, distance 
between the needle and the collector, motion of the target collector, etc. This technique enables 
the production of interesting aligned textures and porous structures and the electrospinning 
parameters can be modified in different ways for combining material properties with different 












Figure 2.1: Schematic electrospinning setup. (A) Polymer melt taken in syringe (B) Nozzle (C) 







2.5.2 Advantages of electrospun nanofibers for tissue engineering: 
 
 The fibers in the nano scale offer much larger scope for engineering and biological 
applications than the conventional fibers. The nano structuring effect of fibers imparts 
many new properties to the system that can be exploited commercially as bacterial filters, 
drug delivery agents, wound healing, etc. [41].  
 Recently, there has been a center of attention given to the applications of nanofibers in 
tissue engineering. TE refers to the efforts of to perform specific biochemical functions 
using cells with an artificially created support system that may compromise various 
materials and then interaction with the human body environment. Electrospun nanofiber 
matrices show morphological similarities to the natural extracellular matrix characterized 
by ultrafine continuous nanofibers, high surface to volume ratio, high porosity and 
variable pore size distribution and have properties that can modulate the cellular 
behavior. These properties make them ideal and best suited to produce biological 
scaffolds [42].  
 In order to guide and orient cells in soft TE, such as the myocardial tissue which has an 
aligned texture, scaffolds with an aligned texture are desirable which can be produced by 
the electrospinning process. The cells take cues from the electrospun nanofibrous 
topography and maintain their appropriate phenotypes and lay down the ECM in vivo 







Human cardiomyocyte interaction with electrospun fibrinogen/gelatin nanofibers for 
myocardial regeneration   
 
3.1 Introduction 
Myocardial Infarction leads to end-stage heart failure and it is the major cause of death in many 
industrialized nations. Tissue engineering approaches for treatment of the infarcted tissue has 
gained huge attention over the recent years and research in this direction mainly aims for the 
optimization of a biomaterial scaffold with cell-source for tissue regeneration. In this regard, we 
fabricated a composite, but absolutely natural polymeric scaffold, using the blood protein, 
namely fibrinogen and the denatured collagen glycoprotein or gelatin by electrospinning process. 
Scaffolds with two different weight ratios of fibrinogen:gelatin (Fib:Gel) was prepared and 
cross-linking (CL) of the electrospun scaffolds was carried out using glutaraldehyde vapors for a 
short period of time to improve the mechanical properties of the scaffolds [Fib/Gel(1:4)-CL; 
Fib/Gel(2:3)-CL]. We evaluated the morphological, chemical and mechanical properties of the 
fabricated the natural polymeric scaffolds and identified the optimal amount of fibrinogen in the 
fabricated natural composite. Further, we supplemented the scaffolds with human 
cardiomyocytes and studied the attachment and proliferation of the cardiomyocytes and analyzed 
the cell-scaffold interactions to determine the suitability of the fabricated scaffolds for 
myocardial TE.  
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3.2 Materials and methods 
3.2.1 Materials  
Gelatin type A, Fibrinogen from bovine plasma, and 1,1,1,3,3,3 – hexafluoro-2-propanol (HFP) 
were purchased from Sigma-Aldrich (Singapore). Human cardiomyocytes and the Myocyte 
Growth Medium were purchased from Promocell, Germany. Dulbecco modified eagle’s medium 
(DMEM), fetal bovine serum (FBS), phosphate buffered saline (PBS), antibiotics and trypsin-
ethylenediaminetetraacetic acid (EDTA) were purchased from Gibco, Invitrogen Corp., USA. 
Hexamethyldisilazane (HMDS) and polyvinylalcohol mounting medium were obtained from 
Fluka, Singapore and CellTiter96 Aqueous one solution was purchased from Promega (WI, 
USA). Monoconal anti-α-actinin, anti-troponin-T, anti-connexin-43, anti-cardiac myosin heavy 
chain produced in mouse were all purchased from Abcam, Hongkong.   
3.2.2 Fabrication of scaffolds by electrospinning 
Fibrinogen was dissolved in HFP by stirring for a period of 24 hours and gelatin was further 
added to make a total of 10% (w/v) solution. Two different compositional ratios of fibrinogen: 
gelatin, namely 20:80 (Fib/Gel 1:4) and 40:60 (Fib/Gel 2:3) was prepared. The polymer solutions 
were electrospun from a 3-mL syringe using a 0.5 mm blunted stainless steel needle at a high 
voltage of 15 KV to obtain Fib/Gel (20:80 & 40:60) nanofibers. The flow rate of the polymer 
solutions was maintained at 0.85 mL/h using a syringe pump (KD Scientific, Holliston, USA) 
and the drawn fibers were collected on a flat aluminum foil wrapped around the collector or on 
15 mm glass cover slips placed at a distance of 10 cm from the needle tip.  The electrospinning 
process was conducted at room temperature (RT) and at a humidity of 50%. The collected 
electrospun Fib/Gel (1:4 and 2:3) nanofibers were vacuum dried to remove any residual solvent 
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present. Fibrinogen was dissolved in HFP at a weight ratio of 12% and electrospun at a high 
voltage of 20 kV to obtain pure fibrinogen fibers, which served as the control scaffold. The 
collected pure fibrinogen nanofibers were vacuum dried to remove any residual solvent present 
and were used as a control for characterization and cell culture experiments.   
3.2.3 Glutaraldehyde cross-linking 
The electrospun Fib/Gel (1:4 and2:3) and pure fibrinogen nanofibers were cross-linked using 
glutaraldehyde vapors to improve their mechanical integrity and structural stability. In short, the 
electrospun nanofibers were placed in a petri dish and kept under 50 % glutaraldehyde vapors at 
RT in a closed container. The cross-linking time was limited to 30 minutes in order to maintain 
the non-cytotoxic nature of the natural polymeric nanofibers. The cross-linked nanofibrous 
scaffolds were vacuum dried for 24 – 48 hours.  
The composite scaffolds of Fib/Gel nanofibers after crosslinking were named as   Fib/Gel(1:4)-
CL and Fib/Gel(2:3)-CL, respectively for Fib/Gel (1:4) and Fib/Gel (2:3) nanofibers. The cross-
linked fibrinogen scaffolds were named as Fib-CL throughout this manuscript. 
3.2.4 Morphological, chemical and mechanical characterization of the electrospun natural 
polymeric nanofibrous scaffolds 
The cross-linked electrospun nanofibrous scaffolds were sputter coated with gold (JEOL JFC-
1200 Auto Fine Coater, Japan) and the morphology was analyzed using scanning electron 
microscopy (JSM5600, JEOL, Japan) at an accelerating voltage of 10 – 20 KV. Image analysis 
software (Image J, National Institutes of Health, USA) was used to determine the diameter of the 
nanofibers from the SEM micrographs.  
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Attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopic analysis of the 
cross-linked electrospun nanofibrous scaffolds was done using Avatar 380 (Thermo Nicolet, 
Waltham, MA) over a range of 1000 – 3500 cm-1 at a resolution of 4 cm-1.  
The wettability or the hydrophilic/hydrophobic nature of the cross-linked electrospun 
nanofibrous scaffolds was measured by drop water contact angle measurement using VCA 
Optima Surface Analysis System (AST products, Billerica, MA). The cross-linked electrospun 
nanofibers on coverslips were placed on the testing plate under the needle and deionized water 
was used for drop formation. The droplet size was 0.5 µl.  
The tensile properties of the cross-linked electrospun nanofibrous scaffolds were obtained using 
Instron table-top tensile tester (Instron 5943, MA, USA) at a load cell capacity of 10 N, cross 
head speed of 5 mm/min and gauge length of 20 mm under ambient conditions of 24
o
C and 34% 
humidity. The scaffolds were soaked in PBS for a time period of 24 hours and the mechanical 
strengths of the PBS-soaked scaffolds were also evaluated during this study. The specimen 
preparation was done by cutting the cross-linked electrospun scaffolds to rectangular shape of 
dimensions 10 mm breadth x 30 mm length. Six specimens of each scaffold type were tested and 
the stress-strain curve was plotted. The tensile stress-strain values obtained from the instrument 
were plotted using an Excel sheet.  
 
3.2.5 Cell culture on the electrospun scaffolds 
Four separate samples were prepared during this study: Fib/Gel(1:4)-CL, Fib/Gel(2:3)-CL, Fib-
CL and the control tissue culture plate (TCP). The electrospun fibers collected on 15 mm 
diameter glass cover slips were placed in a 24-well plate, pressed with a stainless steel ring and 
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sterilized under UV light for 2 hours. The electrospun scaffolds on the cover slips were washed 
thrice with PBS at an interval of 15 minutes each to remove any residual solvent or crosslinking 
agent, and soaked in DMEM overnight before cell seeding. Human cardiomyocytes were 
cultured in myocyte growth medium supplemented with 10% FBS and 1% antibiotics (penicillin 
100 units ml
-1
 and streptomycin 100 µg ml
-1
) in 75 cm
2
 cell culture flask. The tissue culture flask 
was kept in an incubator at 37
o
C with 5% CO2, and the media was changed every alternate day. 
After the cells became confluent, they were detached from the flask using 1 x Trypsin, 
centrifuged, counted by using a hemocytometer and were seeded onto the scaffolds at a seeding 
density of 10,000 cells per well.  
The proliferation efficiency of the human cardiomyocytes seeded on the electrospun, cross-
linked natural protein substrates was studied over an 8-day period using a colorimetric MTS (3-
(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
inner salt) assay. On days 2, 4, 6 and 8, the media was removed from the 24-well plates and the 
cell-scaffold constructs were washed once with PBS.  The samples were, further added with 20% 
of cell titre reagent and serum-free DMEM and, incubated for 3 hours at 37
o
C in a 5% CO2 
incubator. After 3 hours, the contents were aliquot into a 96-well plate and the absorbance was 
measured at 490 nm using a microplate reader (FLUOstar OPTIMA; BMG Lab Technologies, 
Germany) and the results were exported to Excel sheet.  
The cell morphology of the cell-seeded electrospun construct was studied using SEM. After 8 
days of cell seeding on the nanofibrous substrates, human cardiomyocyte-seeded scaffolds were 
processed for Scanning Electron Microscopy (SEM) evaluation. The cell-scaffold construct was 
washed with PBS and fixed using 3% glutaraldehyde in PBS for 3 hours. The samples were 
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dehydrated with a series of ethanol gradients ranging from 50%, 75%, 90% to 100%. Further, the 
samples were air dried with HMDS, gold coated and subsequently, taken for SEM analysis.  
Immunocytochemical studies were performed for evaluating the functional capability of the 
human cardiomyocytes after seeding them on the electrospun nanofibrous scaffolds. Alpha-
actinin (Act), Troponin I (Trop I), Connexin (Con-43) and Myosin Heavy chain (MHC) were the 
four different cardiac-specific proteins used as cardiac marker proteins of this study. After 8 days 
of cardiomyocyte seeding on the cross-linked electrospun scaffolds, the media was aspirated out 
and the scaffolds were washed with PBS, fixed using formalin for 20 minutes at RT and 
permeated using 0.1% Triton-X100 for 5 minutes at RT. Non-specific sites is blocked using 3% 
bovine serum albumin (BSA) for 90 minutes period. Monoclonal mouse primary antibodies (Act 
and Trop I) were used at a dilution of 1:100 and stained for a period of 90 minutes at RT. The 
samples were then washed thrice with PBS and the secondary antibody (Alexa 488 anti-mouse, 
green) at a dilution of 1:400 and 4’, 6-diamidino-2-phenylindole dihydrochloride (DAPI) at a 
dilution of 1:1000 was added and kept for 90 minutes at RT. The composite scaffolds were also 
immunostained for Con-43 and MHC, using the same protocol as stated above, except that the 
secondary antibody used was AlexaFluor 594 (anti-mouse, red). The cell-scaffold constructs 
were washed with PBS several times to remove the excess staining and the samples were 
mounted onto rectangular glass slides using fluromount and taken for laser scanning confocal 







3.3.1 Morphological, chemical and mechanical characterization of the electrospun natural 
polymeric scaffolds 
Figure 3.1 represents the SEM micrographs of Fib/Gel(1:4)-CL, Fib/Gel(2:3)-CL and the Fib-CL 
scaffolds, obtained as a result of the optimized electrospinning parameters. SEM images of the 
electrospun natural polymeric scaffolds showed uniform randomly oriented beadless fibers in the 
nano-scale range. The fiber diameters of the Fib/Gel(1:4)-CL, Fib/Gel(2:3)-CL and Fib-CL 




Figure 3.1: Morphology of electrospun (A) Fib/Gel(1:4)-CL (B) Fib/Gel(2:3)-CL and  






ATR-FTIR images (Figure 2) of the Fib/Gel(1:4)-CL, Fib/Gel(2:3)-CL and Fib-CL scaffolds 
revealed the presence of the characteristic bands of fibrinogen and gelatin. Fib-CL nanofibers 
showed peaks at 1656 and 1540 cm
-1
 representing amide I and amide II bands which are 
characteristic of proteins with high α-helix content. Fib/Gel(1:4)-CL scaffolds showed peaks at 
1640, 1545, and 1237 cm
-1
 and the Fib/Gel(2:3)-CL scaffolds showed peaks at 1650, 1539 and 
1230 cm
-1
. The peaks shown by the Fib/Gel(1:4)-CL and Fib/Gel(2:3)-CL scaffolds correspond 
to amide I, amide II and amide III bands representing C=O stretching, N-H bending, C-N 
stretching and N-H bending, respectively confirming the triple helical structure of gelatin. There 
was no distinct new peak which shows no particular chemical reaction between the fibrinogen 
and gelatin molecules.  
The hydrophilic/hydrophobic nature of the Fib/Gel(1:4)-CL, Fib/Gel(2:3)-CL and Fib-CL 
scaffolds was measured using drop water contact angle studies. The water-contact angles of the 
Fib/Gel(1:4)-CL, Fib/Gel(2:3)-CL and Fib-CL, along with their fiber diameters are listed in 











Figure 3.2: FTIR spectra of the electrospun nanofibers 
 
Table 3.1 Fiber Diameters and water-contact angles of the electrospun Fib/Gel(1:4)-CL, 













309 ± 18 
 
161 ± 24 nm 
 


















The mechanical properties of the electrospun as such cross-linked scaffolds, as well as the PBS-
soaked (24 hours) scaffolds were determined by evaluation of their tensile strength and strain at 
break. The tensile strength and stiffness properties of the dry and PBS-soaked Fib/Gel(1:4)-CL, 
Fib/Gel(2:3)-CL and Fib-CL scaffolds are listed in Table 3.1 and the mechanical properties of 
the native myocardium are also shown in the table for comparison purposes.  
 
Table 3.2 Tensile strength and stiffness properties of the electrospun Fib/Gel(1:4)-CL, 





Dry Scaffolds PBS-Soaked Scaffolds 


















1.2 0.98 0.061 0.0125 0.009 0.0002 0.003 – 
0.015 







Figures 3.3 & 3.4 show the stress-strain curves of the dry and PBS-soaked fabricated electrospun 
fibers, respectively. The tensile strength and the elastic modulus for the dry Fib/Gel(1:4)-CL 
scaffolds were obtained as 1.2 MPa and 2.5 MPa respectively; and for the dry Fib/Gel(2:3)-CL 
scaffolds the values were 0.98 MPa and 1.84 MPa.  
 
 
Figure 3.3: Stress-strain curves of electrospun and dry scaffolds of Fib/Gel(1:4)-CL, 





The tensile strength of the PBS-soaked scaffolds were found reduced in the order for 
Fib/Gel(1:4)-CL > Fib/Gel(2:3)-CL > Fib-CL scaffolds and the same order was also followed for 
their stiffness values (0.46 MPa, 0.38 MPa and 0.0030 MPa, respectively). However the tensile 
strength and elastic modulus for cross-linked fibrinogen scaffolds (0.061 MPa) was less than that 
of the composite scaffolds, which also highlight the non-feasibility of using pure fibrinogen 
scaffolds for tissue regeneration.  
 
 
Figure 3.4: Stress-strain curves of electrospun PBS-soaked Fib/Gel(1:4)-CL, Fib/Gel(2:3)-CL 




3.3.2 Cell culture studies 
The proliferation efficiency of the cardiomyocytes on the electrospun scaffolds was determined 
by MTS assay which was studied for a period of 8 days. Figure 3.5 shows the results of the MTS 
assay, where the cell proliferation increased with culture time for all the scaffolds and TCP.  
 
 
Figure 3.5: Human cardiomyocyte proliferation on electrospun nanofibers measured by MTS 





The morphology of the human cardiomyocytes grown on the fabricated scaffolds was studied 
using SEM analysis and the results are shown in Figure 3.6. Compared with the fibrinogen 
scaffolds, higher cell attachment was observed on the composite Fib/Gel nanofibers and it was 
found that the nanofibrous topography of the fibers allowed the cardiomyocytes to make 
extensive use of provided cues for isotropic or anisotropic growth.  
 
Figure 3.6: Interaction of Human cardiomyocytes on various substrates (A) Fib/Gel(1:4)-CL (B) 




Immunocytochemistry studies were carried out in detail using four cardiomyocyte specific 
marker proteins – Act, Trop I, Con-43 and MHC. Act is a cardiac-muscle-specific intermediate 
filament protein and is an important constituent of the contractile apparatus [43]. Trop I is a 
calcium receptive protein complex and a key regulatory protein in cardiac muscle contraction 
and relaxation [44]. Con-43 is the main constituent of cardiomyocyte gap junctions and is 
essential for cell-cell coupling and normal cardiac function [45] and MHC is a cardiomyocyte-
specific gene [46].  
Results of the immunocytochemical analysis are shown in Figures 3.7 & 3.8. We observed that 
the Fib-CL scaffolds supported fewer cell growth compared to the cell growth on Fib/Gel(1:4)-
CL and Fib/Gel(2:3)-CL matrices.  
Protein expressions using Con-43 and MHC were carried out on Fib/Gel(1:4)-CL and 
Fib/Gel(2:3)-CL scaffolds and the results which are shown in Figure 3.9, further strengthened the 










Figure 3.7: Cardiac-specific-protein expressions of actinin on Fib/Gel(1:4)-CL, Fib/Gel(2:3)-CL, 
Fib-CL and TCP: (A, D,G, J); cell nuclei stained blue; (B, E, H, K); merged images of cell nuclei 




Figure 3.8: Cardiac-specific-protein expressions of troponin I on Fib/Gel(1:4)-CL, Fib/Gel(2:3)-
CL, Fib-CL and TCP: (A, D,G, J) cell nuclei stained blue; (B, E, H, K) cell troponin stained 






Figure 3.9: Cardiac-specific-protein expressions of connexin on (A) Fib/Gel(1:4)-CL and (B) 







Electrospinning is a simple yet inexpensive method for preparation of fibers in the nano-scale 
range from polymeric solutions by supplying high electric voltage. The electrospun fibers in the 
nanoscale range offer larger scope for TE applications as they possess morphological similarities 
to the native ECM characterized by ultrafine continuous nanofibers, high surface to volume ratio, 
high porosity and variable pore size distribution and have properties that can modulate the 
cellular behavior. In the past decade, electrospinning has become one of the desirable processes 
for fabricating matrices for TE [47, 48]. However, the major requirement for CTE is the 
establishment and maintenance of physiologically high density of viable cells. In the human 
body, the cardiac myocytes are the most physically energetic cells contracting for more than 3 
billion times in an average human lifetime and pumping over 7,000 liters of blood per day along 
100,000 miles of blood vessels. Therefore, it is vital for tissue engineers to apprehend the 
intricacies involved in the cardiac muscle and choose a material which when supplied with 
beating cardiomyocytes does not (i) hinder the contractile effect (ii) increase the diastolic 
stiffness (iii) impede relaxation and (iv) increase the overall wall stresses. Therefore, it would be 
more appropriate to use natural protein based scaffolds, whose physical and mechanical 
characteristics lie within the range of the native myocardium as the basic strategy such that the 
construct provides support to the nascent cardiomyocytes and subsequently integrate into the 
host and biodegrade when assimilation gets completed.  
3.4.1 Importance of the blood plasma protein – fibrinogen in myocardial regeneration 
Fibrinogen is a naturally occurring, globular blood plasma protein with a molecular mass of 
340,000 Da. The pathophysiological process following an injury involve fibrinogen undergoing 
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several complex coagulation processes leading to the formation of fibrous structures which have 
the property to facilitate as nature’s provisional matrix based on which further repair of the tissue 
takes place. In the case of the myocardium, fibrinogen along with fibronectin is crucial for the 
formation of “primary matrix” (in developing the granulation tissue) which functions as a 
meshwork for the deposition and adhesion of other matrix proteins such as interstitial collagens 
post MI [49, 50]. It has been observed that the fibrinogen infiltrates to individual 
cardiomyocytes, approximately 12 to 24 hours post MI and construct the framework for the 
primary matrix. Also, the degradation products of fibrinogen like the smaller fragments of 
peptides are found to show very unique properties such as (i) improve healing promotion both in 
vitro and in vivo [51] (ii) protective effect against myocardial reperfusion injury in rats because 
of its ability to prevent leukocyte migration (iii) reducing infarct size (iv) preserving the 
endothelial barrier function and alleviating the myocardial reperfusion injury [52, 53]. 
Fibrinogen has the ability to bind to a wide array of molecules that are favorable from a CTE 
perspective and it also contains RGD integrin binding sites and has the capacity to bind with 
functional VEGF, fibroblast growth factor and several other cytokines [54, 55]. However, in the 
past two decades, researchers figured out that fibrinogen, when present in higher levels in the 
heart, represent a major and independent risk factor for MI [56 - 58] and other cardiovascular 
diseases. There was it was also essential to determine the optimum amounts of fibrinogen that 
could be utilized for the fabrication of composite scaffolds, for application in CTE.  
 We obtained fibrinogen nanofibers with diameters much closer to that of the native fibrinogen 
present in plasma clots [59]. Being a natural protein, such smaller diameter fibers may encounter 
breakage during contraction/relaxation or degrade at a very early stage as they do not possess the 
mechanical integrity and structural stability when used as a myocardial TE substrate. However, 
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with incorporation of gelatin, an increase in concentration of gelatin in the polymer solution 
resulted in increased fiber size for the composite scaffolds. Fib/Gel(1:4)-CL scaffolds presented 
the appropriate fiber morphology and diameter in the range of 300 nm which was found similar 
to that of the native proteins in the ECM of nearly 300 nm [60]. The electrospun Fib/Gel 
nanofibrous composite scaffolds were cross-linked using glutaraldehyde vapors for a limited 
time. Though various physical (UV-irradiation, dehydrothermal treatment) and chemical 
(formaldehyde, glutaraldehyde, carbodiimide, dextran dialdehyde) cross-linking methods are 
currently available, glutaraldehyde is still considered as the most effective cross-linking agent for 
collagenous proteins [61]. Glutaraldehyde cross-linking is found to be advantageous in 
decreasing the bio-degradation, improving the thermal stability, biological and mechanical 
integrity, strength and flexibility [62]. The risk of inducing toxicity can be lowered by decreasing 
the concentration of glutaraldehyde and the cross-linking time [63]. Pure gelatin nanofibers were 
fabricated by Zhang et al [64] and the glutaraldehyde cross-linked gelatin nanofibers were 
described to maintain the fiber morphology. These researchers evaluated the cytotoxicity of the 
scaffolds by culturing human dermal fibroblasts and they found a linear increase in cell growth 
over the culture time. In our study, we minimized the slightest possibility of introducing toxicity 
to the natural polymeric scaffolds by containing the cross-linking time to a very limited time 
period. It was also found from our experiment that cross-linking did not affect the surface 
properties of the Fib/Gel scaffolds. The pure fibrinogen scaffolds were hydrophobic and the 
Fib/Gel(1:4)-CL substrates with the least concentration of fibrinogen (20%) showed highest 
hydrophilicity. By reducing the content of fibrinogen within the composite (Fib/Gel), we were 
able to improve the hydrophilicity of the composite scaffold. Hence the Fib/Gel(1:4)-CL  
scaffolds were more hydrophilic than the Fib/Gel(2:3)-CL  scaffolds . Gelatin contains hydroxyl 
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groups which can form hydrogen bonds with the water molecules thereby providing higher 
hydrophilicity to Fib/Gel(1:4)-CL scaffolds.  
The mechanical properties of the scaffolds are very critical, in particular, for scaffolds used for 
CTE. The objective of this study being to imitate the myocardial ECM, which means the 
fabricated substrate should possess some of the intrinsic mechanical properties of the native 
cardiac tissue. It is understood that one of the major consequences of MI is heart wall thinning 
and ventricular dilation which tremendously increases the heart wall stresses. In such cases, the 
use of a biomimetic polymeric scaffold should help in simple changes in ventricular geometry 
resulting in the reduction of elevated local wall stresses. Synthetic polymers have very high 
stiffness and when used as a myocardial construct it will result in diastolic dysfunction causing 
overstress of heart walls leading to progressive structural and functional changes in ventricles, 
prompting the end stage of heart failure. Natural polymers are often ignored accounting to their 
inferior mechanical strengths. But, for the purpose of CTE, it is essential to understand the innate 
mechanical properties of the heart wall and use an appropriate polymer to avoid such serious 
consequences. The stiffness of a healthy heart muscle is in the range of 10 – 20 KPa at the early 
stage of diastole and rise upto 50KPa at the end of diastole [65, 66]. These values should be used 
as the upper and lower limits of stiffness when choosing a suitable biomaterial for application as 
a cardiac construct.  
From Table 3.2, we can see that the fabricated Fib/Gel scaffolds showed tensile and stiffness 
properties comparable to that of the native myocardium. Since the ECM of myocytes is collagen, 
it is presumed that the cardiomyocytes could beat adequately in a scaffolding material with 
mechanical properties analogous to that of myocardial collagen, which also demonstrate the 
feasibility of using our electrospun Fib/Gel(1:4)-CL scaffolds for CTE. Human cardiomyocyte 
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cell proliferation was found significantly higher in the Fib/Gel scaffolds, in particular, the 
Fib/Gel(1:4)-CL, demonstrating their ability to cause better cell adhesion and proliferation 
compared to the Fib/Gel(2:3)-CL scaffolds. The Fib-CL scaffolds showed minimal proliferation 
which might be due to the inability of pure fibrinogen to support cell proliferation. SEM images 
of the matrices populated with cardiomyocytes showed that cell growth and cell spreading was 
more predominant on the Fib/Gel(1:4)-CL scaffolds. This can be attributed to the fact that gelatin 
has several integrin binding sites for cell adhesion and proliferation [67] and also that fibrinogen 
when present in optimized levels might positively assist the cell growth. Immunocytochemistry 
results showed that the Fib/Gel scaffolds contained greater number of cells with the cell nuclei 
surrounded with mature cytoskeleton and the functional integration of the human 
cardiomyocytes was found to be more pronounced on the Fib/Gel(1:4)-CL scaffolds. Also, from 
our work, we have established the fact that fibrinogen is an indispensable factor before and after 
MI. Moreover, we cannot neglect the use of fibrinogen as they favor the development of 
granulation tissue post MI and their potential advantage can be understood from the synonymity 
displayed by the Fib/Gel(1:4)-CL scaffolds to the myocardial ECM. We established the 
importance of using pure natural protein nanofibers as suitable substrates for restoring the 









An impairment in the functioning of the heart due to an infarction, demand the cardiac muscle 
for a simple, fundamental necessity, manifested by an artificial cell-construct/matrix that can 
support the native tissue provide cues for heart tissue regeneration. We found that 
electrospinning a composite scaffold of fibrinogen and gelatin, which contains an optimized 
amount of fibrinogen, can act as a substrate suitable for cell growth and proliferation, and might 
enable the regeneration of the myocardial tissue. Our work highlight the outstanding 
resemblance of the fabricated natural polymeric Fib/Gel(1:4)-CL composite cell-constructs to 
that of the native myocardial ECM in terms of morphology, surface characteristics, tensile 
strength and stiffness properties and emphasize their compatibility and efficiency for the 
proliferation of human cardiac cells placing them in the forefront as the best candidates for 














Electrospun collagen/fibrinogen nanofibrous scaffolds enhance cardiomyogenic 
differentiation of adipose-derived stem cells for myocardial tissue engineering 
4.1 Introduction 
Human adipose-derived stem cells (ADSCs) possess the ability to differentiate along multiple 
lineage pathways and they can be easily isolated by a simple, minimally invasive method and in 
large numbers. ADSCs represent a beneficial source of cardiomyocyte progenitors and they are 
promising candidates to be used in CTE. ADSCs are gaining rapid focus among tissue engineers 
mainly because of their several useful properties. In this study, we investigated the in vitro 
cardiac differentiation of human ADSCs in co-culture with human cardiomyocytes on 
electrospun natural polymeric nanofibrous scaffolds. We fabricated a completely natural 
polymeric nanofibrous composite scaffold using the ubiquitous body protein, collagen and the 
blood plasma protein, fibrinogen. The optimized amount of fibrinogen in the natural composite 
was identified from our previous experiment (Chapter 3). Cross-linking using glutaraldehyde 
vapors was carried out for a short period of time to enhance the mechanical integrity of the 
fabricated matrices. Morphological, chemical and mechanical properties of the developed natural 
polymeric composite scaffolds were studied. The cell-scaffold interactions were analyzed by 
evaluating the cell proliferation using MTS assay, and SEM analysis was done to determine the 
cell morphology. Dual immunofluorescent staining was performed to further confirm the 
cardiogenic differentiation of ADSCs by using cardiac-specific marker proteins MHC and 
CD105.  In vitro cardiomyogenic differentiation of human ADSCs in co-culture with human 
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cardiomyocytes on the natural polymeric composite scaffolds proved the suitability of our 
electrospun fibrinogen/collagen nanofibrous matrices for CTE.  
4.2 Materials and Methods 
4.2.1 Materials 
Atellocollagen powder was obtained from Kokimo, Japan. Human ADSCs were got from Lonza, 
Singapore and cardiac-specific marker protein CD 105 was purchased from Abcam, Hong Kong.  
4.2.2 Fabrication of scaffolds by electrospinning 
Fibrinogen was dissolved in HFP by stirring for a period of 24 hours and collagen was further 
added to make a total of 10% (w/v) solution. From our previous experiment, the optimum 
amount of fibrinogen in the natural composite was identified and according to that result, the 
fibrinogen:collagen (Fib/Coll) solution was prepared to a ratio of 20:80. The polymer solution 
was electrospun from a 3-mL syringe using a 0.5 mm blunted stainless steel needle at a high 
voltage of 15 KV to obtain Fib/Col (20:80) nanofibers. The flow rate of the polymer solution 
was maintained at 0.85 mL/h using a syringe pump (KD Scientific, Holliston, USA) and the 
drawn fibers were collected on a flat aluminum foil wrapped around the collector or on 15 mm 
glass cover slips placed at a distance of 10 cm from the needle tip.  The electrospinning process 
was conducted at RT and at a humidity of 50%. The collected electrospun Fib/Coll (20:80) 
nanofibers were vacuum dried to remove any residual solvent present.  
Pure fibrinogen nanofibers were prepared as described in Chapter 3 (Section 3.2.2). The 
collected pure fibrinogen nanofibers were vacuum dried to remove any residual solvent present 
and were used as a control for characterization and cell culture experiments.   
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4.2.3 Glutaraldehyde cross-linking 
The electrospun Fib/Coll (20:80) and pure fibrinogen nanofibers were cross-linked using 
glutaraldehyde vapors (described in Section 3.2.3) to improve their mechanical integrity and 
structural stability. The composite scaffolds of Fib/Coll (20:80) nanofibers after crosslinking 
were named as   Fib/Coll(1:4)-CL and the cross-linked fibrinogen scaffolds were named as Fib-
CL throughout this manuscript. 
The morphological, chemical and mechanical characterization of the electrospun Fib/Coll(1:4)-
CL nanofibers were carried out as described in Section 3.2.4. 
4.2.4 Cell culture on the electrospun scaffolds 
The electrospun fibers collected on 15 mm diameter glass cover slips were placed in a 24-well 
plate, pressed with a stainless steel ring and sterilized under UV light for 2 hours. The 
electrospun scaffolds on the cover slips were washed thrice with PBS at an interval of 15 minutes 
each to remove any residual solvent or crosslinking agent, and soaked in DMEM overnight 
before cell seeding. Human cardiomyocytes were cultured in myocyte growth medium 
supplemented with 10% FBS and 1% antibiotics (penicillin 100 units ml
-1
 and streptomycin 100 
µg ml
-1
) in 75 cm
2
 cell culture flask. The human ADSCs were cultured in low-glucose DMEM 
supplemented with 10% FBS and 1% antibiotic in a 150 cm
2
 cell culture flask. The tissue culture 
flasks were kept in an incubator at 37
o
C with 5% CO2, and the media was changed every 
alternate day. After the cells became confluent, they were detached from the flask using 1 x 
Trypsin, centrifuged and counted by using a hemocytometer.  
The scaffolds were separated into three groups: Fib/Coll(1:4)-CL, Fib-CL and TCP. In order to 
perform co-culture, human ADSCs and human cardiomyocytes were seeded onto the scaffolds in 
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the ratio of 1:1 at a seeding density of 4, 000 cells per well (2000 ADSCs:2000 cardiomyocytes). 
The proliferation efficiency of the human ADSCs and cardiomyocytes (co-culture) seeded on the 
electrospun, cross-linked natural protein substrates was studied over a 21-day period using a 
colorimetric MTS (3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt) assay. On days 7, 14 and 21, the media was removed 
from the 24-well plates and the cell-scaffold constructs were washed once with PBS.  The 
samples were, further added with 20% of cell titre reagent and serum-free DMEM and, incubated 
for 3 hours at 37
o
C in a 5% CO2 incubator. After 3 hours, the contents were aliquot into a 96-
well plate and the absorbance was measured at 490 nm using a microplate reader (FLUOstar 
OPTIMA; BMG Lab Technologies, Germany) and the results were exported to Excel sheet.  
After 21 days of cell seeding on the nanofibrous substrates, the cell-seeded scaffolds were 
processed for SEM evaluation to study the morphology. The cell-scaffold constructs were 
washed with PBS and fixed using 3% glutaraldehyde in PBS for 3 hours. The samples were 
dehydrated with a series of ethanol gradients ranging from 50%, 75%, 90% to 100%. Further, the 
samples were air dried with HMDS, gold coated and subsequently, taken for SEM analysis.  
Immunocytochemical studies were performed for evaluating the functional capability of the 
human ADSCs and cardiomyocytes after seeding them on the electrospun nanofibrous scaffolds. 
The three groups of samples -  Fib/Coll(1:4)-CL, Fib-CL and TCP, were further separated into 
co-culture scaffolds onto which human ADSCs and human cardiomyocytes were seeded in the 
ratio of 1:1 at a seeding density of 4, 000 cells per well (2000 ADSCs:2000 cardiomyocytes); 
positive control scaffolds, onto which cardiomyocytes were seeded at the same seeding density 
of 4, 000 cells per well; and the final set consisted of negative control scaffolds, onto which 
human ADSCs were seeded at the same seeding density of 4, 000 cells per well.  
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 MHC and CD 105 were the two different cardiac-specific proteins used as cardiac markers in 
this study. After 21 days of seeding on the cross-linked electrospun scaffolds, the media was 
aspirated out and the scaffolds were washed with PBS, fixed using formalin for 20 minutes at RT 
and permeated using 0.1% Triton-X100 for 5 minutes at RT. Non-specific sites is blocked using 
3% bovine serum albumin (BSA) for 90 minutes period. Monoclonal mouse primary antibodies 
(MHC) were used at a dilution of 1:100 and stained for a period of 90 minutes at RT. The 
samples were then washed thrice with PBS and the secondary antibody (Alexa 488 anti-mouse) 
at a dilution of 1:400 and 4’, 6-diamidino-2-phenylindole dihydrochloride (DAPI) at a dilution of 
1:1000 was added and kept for 90 minutes at RT.  
Double immunofluorescent staining was further performed on the co-culture scaffolds to confirm 
the differentiation of human ADSCs into cardiomyocytes. The ADSC-cardiomyocyte co-culture 
cells plated on Fib/Coll(1:4)-CL, Fib-CL and TCP were stained with cardiac-speciﬁc marker 
MHC in the dilution 1:100 for 90 minutes at RT, before which the nonspeciﬁc sites were blocked 
with 3% bovine serum albumin. This was followed by the addition of secondary antibody Alexa 
Fluor 488 (anti mouse, green) in the dilution 1:400 and DAPI at a dilution of 1:1000 and kept for 
90 minutes at RT. The samples were washed with PBS thrice to remove the excess staining. The 
samples were then treated with cardiac-speciﬁc marker protein CD 105 in the dilution 1:100 for 
90 minutes at RT. This was followed by the addition of the secondary antibody Alexa Fluor 594 
(anti mouse, red) in the dilution 1:400 for 90 minutes at RT. The samples were washed with PBS 
thrice to re-move the excess staining. The samples were then removed and mounted over a 
rectangular glass slides using fluromount and taken for confocal microscopic analysis.  
The pure culture scaffolds of human ADSCs were stained using the marker protein CD 105 and 
secondary antibody Alexa Fluor 594 (anti-mouse, red) and the pure culture scaffolds of human 
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cardiomyocytes were stained using the cardiac-specific protein MHC and the secondary antibody 
Alexa Fluor 488 (anti mouse, green) following the same procedure. 
4.3 Results and Discussion 
4.3.1 Importance of collagen in myocardial regeneration 
After MI, the collagen network is damaged and this weakened collagen network leads to wall 
thinning and ventricular dilation. Infarct expansion is closely associated with the impairment of 
the collagen network of the heart which is due to apparent loss of collagen struts which provide 
the additional damage essential for significant expansion. Further, when collagen has been 
deposited in the infarct to form the scar tissue, the infarcted myocardium becomes capable to 
resist further expansion to a certain extent suggesting that damaged collagen network is 
vulnerable while normal collagen is able to withstand expansion [68]. Therefore, efficient and 
rapid deposition of type I collagen is fundamental for healing since the collagen matrix provides 
a mechanically strong network, minimizes infarct expansion and resists maladaptive remodeling 
[69]. It is suggested that in spite of the deleterious consequences of degrading collagen fibrils, 
cleavage of type I collagen is essential for effective fibrotic healing after MI [70].  
We fabricated fully natural, nanofibrous composite scaffolds using collagen and fibrinogen and 
cross-linked them using glutaraldehyde for a short period of time to enhance their mechanical 
properties. Figure 4.1 represents the SEM micrographs of Fib/Coll(1:4)-CL and the Fib-CL 
scaffolds, obtained as a result of the optimized electrospinning parameters. SEM images of the 
electrospun natural polymeric scaffolds showed uniform randomly oriented beadless fibers in the 
nano-scale range. The fiber diameters of the Fib/Coll(1:4)-CL and Fib-CL scaffolds were in the 
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range of 287 ± 10 nm and 133 ± 12 nm, respectively which is comparable to that of the natural 
proteins in the ECM [60].  
 
 
Figure 4.1: SEM morphology of electrospun (A) Fib/Coll(1:4)-CL and (B) Fib-CL nanofibers 
  
The ATR-FTIR images of the Fib/Coll(1:4)-CL and Fib-CL scaffolds are shown in Figure 4.2. 
The peaks seen at 3200 and 3048 cm
-1
 are characteristic of collagen and represent the N-H 
stretching and C-H stretching, respectively. The peaks at 1650, 1587 and 1230 cm-1 correspond 
to amide I, amide II and amide III bands representing C=O stretching, N-H bending, C-N 
stretching, respectively confirming the triple helical structure of collagen. There was no distinct 



















Drop water contact angle studies were performed to determine the hydrophilic/hydrophobic 
nature of the Fib/Coll(1:4)-CL and Fib-CL scaffolds. Table 4.1 lists the water-contact angle 
measurements of the fabricated scaffolds. 









Fiber Diameter (nm) 
 
287 ± 10 
 











The tensile strength and stiffness properties of the dry and PBS-soaked Fib/Coll(1:4)-CL and 
Fib-CL scaffolds were determined and the values are listed in Table 4.2. It can be observed from 
the table that the fabricated Fib/Coll(1:4)-CL scaffolds show tensile strength and stiffness 
properties comparable to that of the heart muscle. Figures 4.3 & 4.4 show the stress-strain curves 
of the dry and PBS-soaked, electrospun Fib/Coll(1:4)-CL and Fib-CL fibers, respectively.  








Fib/Coll(1:4)-CL Fib- CL Fib/Coll(1:4)-CL Fib-CL 
Tensile Strength(MPa) 1.56 0.061 0.0143 0.0002 
Stiffness(MPa) 2.90 0.830 0.5300 0.0030 
























4.3.2 Myocardial regeneration potential of adipose-derived stem cells 
MI is considered to be one of the most challenging heart diseases for treating because it is 
irreversible and the cardiomyocytes do not possess the intrinsic regenerative capability to replace 
the lost cells. In principle, stem cells are the optimal cell source for myocardial tissue 
regeneration because they possess the ability to differentiate into one or more specialized cells, 
self-renew and produce unlimited number of stem cell progeny with similar properties 
throughout the lifetime [71, 72]. ADSCs demonstrate to differentiate along various mesenchymal 
lineages – adipogenesis, chondrogenesis, osteogenesis, myogenesis, etc. and also non-
mesenchymal lineages like skeletal myogenesis, cardiogenesis, neurogenesis, etc. [73]. In 
addition to their good regeneration potential, ADSCs are also preferred for practical reasons. 
They are free of ethical, oncological and immunological concerns present in pluripotent stem 
cells. They are present in abundance, less invasive and less time-consuming to obtain compared 
to other tissue sources such as heart, skeletal muscle or bone marrow [74, 75]. Also, adipose 
tissue possess a higher stem cell density (5%) than the bone marrow (0.001%) [76]. The adipose 
tissue consists of mature adipocytes, preadipocytes, fibroblasts, vascular smooth muscle cells, 
endothelial cells, resident monocytes/macrophages and lymphocytes [77, 78]. ADSCs can be 
obtained in large amounts using liposuction procedure. The stromal-vascular cell fraction (SVF) 
of the adipose tissue is a rich source of pluripotent ADSCs and has become the focus of research 
for TE applications [79, 80]. Mature adipocytes are produced from the SVF, when the adipose 
tissue is collagenase digested. SVF shows phenotype characteristic of various populations 
including multipotent stem cells, hematopoietic, endothelial, smooth muscle cells, etc. [81]. The 
ADSCs are potent paracrine mediators and they are found to have significant effect on the 
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evolution of the ischemic myocardium [82 – 85]. The direct differentiation of transplanted cells 
and the paracrine actions upon damaged tissue is shown in Figure 4.5 [86].  
 
 
Figure 4.5: Adipose-derived cells are capable of direct differentiation and  






Several animal studies have demonstrated the differentiation potency of ADSCs into 
cardiomyocytes [87] and reported that ADSCs can be useful to alleviate cardiac function in 
animals in vivo [88]. ADSCs co-cultured with rat cardiomyocytes demonstrated better 
differentiation expressed cardiac markers such as Act, Trop I and MHC. The ADSCs also 
showed contractions synchronous with the rat cardiomyocytes (upto 106 beats/min) [89]. In vivo 
differentiation study demonstrated that human ADSCs co-cultured with neonatal rat 
cardiomyocytes at 1:10 ratio in a vascularized cardiac tissue engineering model showed 
contractions of 140 beats/min. The ADSC-cardiomyocytes co-cultured group grew nearly twice 
as much vascular tissue in the construct than the cardiomyocyte group55% and 26% larger, 
respectively [90]. Immunocytochemical studies reported differentiation into cardiomyocytes, 
smooth muscle cells, adipocytes, recruitment into vascular structures, paracrine recruitment of 
endothelial cells and integration with the co-cultured rat cardiomyocytes. 
In order to prove that the fabricated natural polymeric scaffolds enhance differentiation of stem 
cells, we performed co-culture of human ADSCs along with human cardiomyocytes. The 
proliferation efficiency of the human ADSCs on the electrospun Fib/Coll(1:4)-CL, Fib-CL 
scaffolds and TCP after 7, 14 and 21 days was determined by MTS assay. The cell proliferation 
on Fib/Coll scaffolds was higher than that on the Fib-CL scaffolds and TCP. This is because of 
the presence of the natural myocardial ECM protein collagen and also the presence of fibrinogen 
(which helps in the formation of granulation tissue post MI) in optimal amount. Fig 4.6 shows 
the results of the MTS assay, where the cell proliferation increased with culture time for all the 







Figure 4.6: Cell proliferation study of human ADSCs- co-cultured with human cardiomyocytes. 




The cell morphology of the differentiated ADSCs was studied using SEM images (Figure 4.7). 
Nanotopography is critical in TE as nanoscale dimensions are capable of modulating cellular 
responses and it can influence cell morphology, adhesion motility, proliferation, protein 
expression and gene regulation [91]. Compared with the fibrinogen scaffolds, higher cell 
attachment was observed on the composite Fib/Coll nanofibers and it can be seen that the 
fabricated Fib/Coll(1:4)-CL nanofibrous topography provided the necessary cues for 
differentiation of the human ADSCs into cardiomyocytes, integration with the co-cultured 
human cardiomyocytes and also for their isotropic or anisotropic growth.  
 
 
Figure 4.7 SEM images showing the morphology of ADSC-cardiomycytes co-culture cells on 






To observe the myocardiogenic differentiation of the seeded human ADSCs, 
immunofluorescence stains of specific cardiomyocyte marker proteins like MHC and CD 105 
were analyzed. The cardiac-specific marker protein expression is predominant in the co-culture 
system than the positive (pure culture of human cardiomyocytes) and negative control (pure 
culture of human ADSCs) groups. Figure 4.8 shows the cardiac protein expression using MHC 
on cardiomyocytes (pure culture) and as can be seen from Figure 4.9, the ADSCs express the 
ADSC-specific marker CD105 (A – C) and they do not express the cardiac-specific protein, 
MHC in their undifferentiated state (D – F), but they express DAPI alone which stains the 
nucleus.  
Dual immunocytochemical staining of the scaffolds using ADSC-specific CD 105 and cardiac-
specific MHC is shown in the Figure 4.10. As can be seen the expression of the cardiac-specific 
protein is predominant in the co-culture system and this is because, the ADSCs that have 
undergone cardiogenic differentiation owing to the presence of cardiomyocytes in close 
proximity also express the marker proteins. In Fib/Coll(1:4)-CL scaffolds, more number of cells 
are found to express both the CD105 and MHC marker indicating that the differentiation is more 
in these scaffolds than in the Fib-CL scaffolds/TCP. This ascertains the fact that our fabricated 
natural composite scaffolds of Fib/Coll(1:4)-CL are best suited for stem cell differentiation and 









Figure 4.8: Cardiac-specific-protein expressions of MHC on Fib/Coll(1:4)-CL, Fib-CL and TCP: 
(A, D,G, J); cell nuclei stained blue; (B, E, H, K); merged images of cell nuclei and MHC. (C, F, 









Figure 4.9: ADSC-specific protein expression of CD105 and MHC on Fib/Coll(1:4)-CL (A, D), 








Figure 4.10: Dual immunofluorescent analysis for the expression of cardiac-specific marker 
protein MHC (A, D, G) and ADSC-specific marker protein CD 105 (B, E, H) and the merged 
image showing dual expression of both MHC and CD 105 (C, F, I) on Fib/Coll(1:4)-CL (A – C), 





In the present study, we fabricated natural polymeric nanofibrous composite scaffolds of 
fibrinogen and collagen using electrospinning and cross-linked them using glutaraldehyde vapors 
– Fib/Col(1:4)-CL. We tested the morphology, chemical properties and mechanical integrity of 
our scaffolds and found them comparable to the native myocardial ECM. We used human 
adipose-derived stem cells which are capable of myocardiogenic differentiation to prove that our 
fabricated Fib/Coll(1:4)-CL substrates supported the differentiation of human ADSCs into 
cardiomyocytes and better cell proliferation, adhesion and integration was also found. In short, 
the fabricated Fib/Coll(1:4)-CL nanofibrous composites, with native tissue-like mechanical 
properties and desirable nanotopographical and stem cell differentiation cues, enhanced the 
differentiation of ADSCs into cardiomyocytes when co-implanted and has the potential to serve 















Conclusion and Recommendations 
5.1 Conclusion 
After MI, the myocardial tissue is scarred, lacks regeneration capabilities and even though, 
compensatory mechanisms occur, the scar tissue is never fully repopulated leading to accelerated 
cardiac failure. Repair of the infarcted myocardium involves three objectives – (i) replacement of 
a new myocardial tissue (ii) formation of a functional vascular network and (iii) restoration of 
the ventricle to its proper geometry. All of these depend on the existence of a temporary matrix 
which could replicate/mimic the myocardial ECM with appropriate mechanical properties, 
thereby not inducing further stress on the ventricular walls. It is important to provide the cells 
with the suitable environmental cues and also, the use of tissue-specific biomaterials will 
promote the possibilities of the success of the tissue engineering approach. It is self-explanatory 
from this fundamental understanding that natural myocardial ECM proteins will be the 
appropriate choice for treating the infarcted myocardium. In the heart tissue, the complex 
structural matrix of the ECM primarily consists of fibrillar collagen type I (80%) and type III 
(11%), and smaller amounts of type IV and type V collagens along with GAGs. Fibrinogen is the 
blood plasma protein which aids the formation of granulation tissue post MI. The importance of 
fibrinogen and collagen for myocardial TE is explained in detail in Section 3.4.1 and Section 
4.3.1, respectively.  
This work has proved the feasibility of employing a completely natural polymeric composite 
scaffold fabricated by the electrospinning process for cardiac regeneration. We have identified 
the optimal amount of fibrinogen in the natural composite and optimized the electrospinning 
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process parameters to obtain nanofibers of appropriate fiber diameter and morphology suitable 
for myocardial TE. The fabricated scaffolds were found to have identical morphological, 
chemical and mechanical properties as the myocardial tissue. Cell culture studies using human 
cardiomyocytes and stem cell differentiation studies were carried out and the results established 
that the fabricated natural protein substrates provided the necessary structural, chemical and 
biological cues for cell-matrix interactions that reflect the natural microenvironment.  
Our work attempts to emulate the myocardial extracellular environment in vitro by the use of 
biomaterials (collagen and fibrinogen) which play a significant role post MI. Materials which are 
currently used for CTE do not provide a cardiac-specific milieu.  
To our knowledge, the use of cardiac-specific protein composite along with human 
cardiomyocytes for the regeneration of the ischemic myocardium is a very novel idea.    
 
5.2 Recommendations 
We have demonstrated the feasibility of fabricating a fully natural polymeric composite matrix 
by electrospinning process for CTE and from the above results, it can be seen that the fabricated 
natural protein scaffolds reflect the cardiac-specific extracellular environment for the cells to 
proliferate and differentiate in vitro.  
From this preliminary study, we can focus on naturally-derived biomaterial-based strategies to 
address and ascertain this novel concept. Future research using cardiac-specific proteins and cells 
can focus on –  
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(i) In vivo animal studies for the regeneration of the injured tissue with the help of 
cardiac-specific biomaterials in the form of an injectable (hydrogel). 
(ii) Engineering a successful 3D tissue construct (ex vivo or in situ) which, eventually, 
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